Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Détails

ID Serval
serval:BIB_86DAF2D9C4DC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
Périodique
Arthritis and Rheumatism
Auteur(s)
So A., De Meulemeester M., Pikhlak A., Yücel A.E., Richard D., Murphy V., Arulmani U., Sallstig P., Schlesinger N.
ISSN
1529-0131[electronic], 0004-3591[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
62
Numéro
10
Pages
3064-3076
Langue
anglais
Résumé
OBJECTIVE: To assess the efficacy and tolerability of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, for the treatment of acute gouty arthritis.
METHODS: In this 8-week, single-blind, double-dummy, dose-ranging study, patients with acute gouty arthritis whose disease was refractory to or who had contraindications to nonsteroidal antiinflammatory drugs and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg; n = 143) or an intramuscular dose of triamcinolone acetonide (40 mg; n = 57). Patients assessed pain using a 100-mm visual analog scale.
RESULTS: Seventy-two hours after treatment, a statistically significant dose response was observed for canakinumab. All canakinumab doses were associated with numerically less pain than triamcinolone acetonide; thus, a dose with equivalent efficacy to triamcinolone acetonide 72 hours after treatment could not be determined. The reduction from baseline in pain intensity with canakinumab 150 mg was greater than with triamcinolone acetonide 24, 48, and 72 hours after treatment (differences of -11.5 mm [P = 0.04], -18.2 mm [P = 0.002], and -19.2 mm [P < 0.001], respectively), and 4, 5, and 7 days after treatment (all P < 0.05). Canakinumab significantly reduced the risk of recurrent flares versus triamcinolone acetonide (P ≤ 0.01 for all doses) (relative risk reduction 94% for canakinumab 150 mg versus triamcinolone acetonide). The overall incidence of adverse events was similar for canakinumab (41%) and triamcinolone acetonide (42%); most were mild or moderate in severity.
CONCLUSION: Our findings indicate that canakinumab 150 mg provides rapid and sustained pain relief in patients with acute gouty arthritis, and significantly reduces the risk of recurrent flares compared with triamcinolone acetonide.
Mots-clé
adrenocorticotropic hormone, triamcinolone acetonide, periodic syndromes, interleukin-1-beta, management, care, hyperuricemia, inhibition, adherence, diagnosis
Pubmed
Web of science
Création de la notice
11/11/2010 11:07
Dernière modification de la notice
03/03/2018 19:00
Données d'usage